Completed
Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients
NCT04790513
- Conditions
- Cardiovascular Diseases, Dyslipidemias, Hypercholesterolemia, +4 more
- Locations
-
- Sterling Research Group Cincinnati, Ohio, United States
- The Lindner Research Center Cincinnati, Ohio, United States
- Metabolic & Atherosclerosis Research Center (MARC) Cincinnati, Ohio, United States